Navigation Links
Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
Date:3/3/2013

New York, New York (PRWEB) March 03, 2013

Pradaxa lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, the next Status Conference in the Pradaxa litigation has been scheduled for March 14, 2013. More than 170 lawsuits have been filed in the litigation by plaintiffs who allegedly suffered serious, life-threatening episodes of Pradaxa bleeding. The Pradaxa lawsuits further allege that Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients, and failed to adequately warn that there was no readily-available antidote for Pradaxa bleeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“Pradaxa bleeding is a frightening side effect, especially because there is no easy way to remedy this occurrence. We are pleased to see this litigation is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to alleged victims of Pradaxa side effects.

Pradaxa Bleeding
Pradaxa was approved for sale by the U.S. Food & Drug Administration (FDA) in October 2012 to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation. According to a recent Bloomberg report, the FDA received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.*

Pradaxa was positioned as an improvement over decades-old warfarin, but an analysis published in the latest QuarterWatch Report from the Institute for Safe Medicine Practices (ISMP) found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.** Warfarin bleeding can be stopped via the administration of vitamin k. However, there is no readily available antidote for Pradaxa bleeding. Dialysis can be used to remove Pradaxa from the blood stream. However, a study published last May in the journal, Neurology, found this treatment is risky and may not be administered in enough time to stop Pradaxa bleeding.** *

According to court documents, the first trials in the federal Pradaxa litigation are scheduled to begin in September 2014. Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more about filing a Pradaxa lawsuit, please visit our website http://www.consumerinjurylawyers.com/, or call 1-877-779-1414 to speak with one of our attorneys today.

*bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html
**ismp.org/quarterwatch/pdfs/2012Q2.pdf
***hejns.org/doi/full/10.3171/2012.2.JNS112132

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb10491817.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
2. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
3. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
4. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
5. Bernstein Liebhard LLP Launches Pradaxa Lawsuit Website Providing Information on Mounting Pradaxa Litigation, Side Effects
6. Pradaxa Side Effect Problems Continue, as New Report Finds Pradaxa Bleeding More Likely to Result in Death, Bernstein Liebhard LLP Reports
7. 176 Pradaxa Lawsuits Now Pending in Federal Litigation, Discovery Well Underway, Bernstein Liebhard LLP Reports
8. DrugRisk Announces New Pradaxa Health Warning From Australia
9. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
10. Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385
11. Pradaxa Side Effect Warning: Pradaxa Label to Warn Blood-Thinner Shouldn’t be Used in People with Mechanical Heart Valves, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: